BNET Industries
Barrier Therapeutics Inc. (BTRX) is in the Pharma Industry
- Revenue
- Dec 31 2007
- $24.0M
- Profit
- Dec 31 2007
- ($53.6M)
- Market Cap
- Jul 02 2008
- $141.2M
Latest News and Analysis
Wall Street News Alert: Breaking News Alert - NTRO! June 24, 2008
Wall Street News Alert's "stocks to watch" thismorning are: Nitro Petroleum, Inc. (OTCBB: NTRO), ConocoPhillips (NYSE: COP), Barrier Therapeutics, Inc. (NASDAQ: BTRX) and Corn ProductsInternational, Inc. (NYSE: CPO). Nitro Petroleum, Inc. (OTCBB: NTRO) continues to make progress, and thecompany should be a "must see" for investors looking to possibly benefitfrom...
Story Stock for Tuesday, June 24, 2008: NPHS Summer Sales Growth!
TheSUBWAY.com announces the following stocks toits Action List: NextPhase Wireless (OTCBB: NPHS), Barrier Therapeutics,Inc. (NASDAQ: BTRX), Royale Energy, Inc. (NASDAQ: ROYL), Level 3Communications, Inc. (NASDAQ: LVLT). Visit TheSUBWAY's Small Cap Investor Forum Here: http://investor-forum.thesubway.com/ NextPhase Wireless, Inc. (OTCBB: NPHS), a nationwide developer ofWiMAX-ready networks and provider of advanced...
BeaconEquity.com Issues TraderNotes on Active Stocks: NLN, GRVY, MDTL, ENER, BTRX, MNKD, ALTI, BG
DALLAS, June 24 /PRNewswire/ -- BeaconEquity.com announces the availability of TraderNotes on stocks that are making news today. Investors can view all of the daily trading notes for free by visiting: http://www.beaconequity.com/ Today's TraderNotes include: National Lampoon Incorporated , Gravity Co. Ltd. , Medis...
Barrier Therapeutics to Merge Into Stiefel Laboratories
Acquisition to enhance industry leader's dermatological portfolio CORAL GABLES, Fla., June 23 /PRNewswire/ -- Stiefel Laboratories Inc., the world's largest independent pharmaceutical company specializing in dermatology, today announced it has signed a definitive merger agreement, pursuant to which Stiefel Laboratories will acquire Barrier Therapeutics, Inc. ("Barrier Therapeutics")...
BellwetherReport.com Analyst Report on BTRX, SOHU, ENER and GTCB
BellwetherReport.com is the leading onlinefinancial newsletter for investors seeking top independent and unbiasedresearch. Investors seeking free and unbiased analyst opinions on thecompanies mentioned in this release are encouraged to sign up to www.bellwetherreport.com for a free subscription to access these reports.Today, we have once again scheduled interviews with a...
Vusion Baby Bottom Line Report: Many Moms Don't Know that Their Babies' Irritated Skin Could Indicate a Severe Diaper Rash that Requires Medical Treatment
- 64% of expectant or new mothers say that diaper rash is only a minor problem - 57% are unaware that diaper rash can be accompanied by a doctor diagnosed yeast infection called Candida, affecting both girls and boys - 59% responded "no" or were unsure...
Zacks Analyst Blog Highlights: I-Flow, Johnson & Johnson, Zimmer Holdings, Stryker and Barrier Therapeutics
CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: I-Flow Corporation (Nasdaq: IFLO), Johnson & Johnson (NYSE: JNJ), Zimmer (NYSE:...
Zacks Bull and Bear of the Day Highlights: Sciele Pharmaceuticals, LoopNet, Newmont Mining, Barrier Therapeutics and BT Group
CHICAGO -- Zacks Equity Research highlights Sciele Pharmaceuticals (Nasdaq: SCRX) as the Bull of the Day and LoopNet, Inc. (Nasdaq: LOOP) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Newmont Mining Corp. (NYSE: NEM), Barrier Therapeutics (Nasdaq: BTRX) and BT Group (NYSE: BT). Full...
Upstream Biosciences Announces Appointment of Dr. Geert Cauwenbergh to Its Board of Directors
Upstream Biosciences Inc. (OTCBB: UPBS) todayannounced the appointment of Geert Cauwenbergh, Ph.D., to its Board ofDirectors. Dr. Cauwenbergh is the founder of Barrier Therapeutics, Inc.,and has been its CEO for the past six years. He has more than 20 yearsexperience in international research, clinical drug development and newproduct commercialization...
Barrier Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results
Barrier Therapeutics, Inc. (NASDAQ: BTRX), apharmaceutical company that develops and markets dermatology products,today announced its financial results for the fourth quarter and year endedDecember 31, 2007. Total revenues increased to $9.7 million for the fourthquarter of 2007 from $7.5 million in the third quarter of 2007, whichrepresents 29% sequential...
Adds Barrier Therapeutics Inc. to our Bluechips Radar.
M2 PRESSWIRE-7 January 2008-International Stock Targets: Adds Barrier Therapeutics Inc. to our Bluechips RadarC1994-2008 M2 COMMUNICATIONS LTD RDATE:07012008 International Stock Targets has announced a "Strong Buy" recommendation along with a one-month and six-month price target for our newest...
Barrier Therapeutics Announces 2008 Financial Guidance and Updates 2007 Financial Guidance
Barrier Therapeutics, Inc. (NASDAQ: BTRX), apharmaceutical company that develops and markets dermatology products,today announced its 2008 financial guidance and updated its guidance for2007. Full Year 2008 Financial Guidance: -- Total revenues are expected to increase to between $46 million to $50 million, which would be approximately...
Barrier Therapeutics Announces Third Quarter 2007 Financial Results
Barrier Therapeutics, Inc. (NASDAQ: BTRX), apharmaceutical company that develops and markets dermatology products,today announced its financial results for the third quarter ended September30, 2007. Total revenues increased to $7.5 million for the third quarterof 2007 from $4.1 million in the second quarter of 2007, and represent 83%sequential growth. ...
Barrier Therapeutics to Release Third Quarter 2007 Financial Results on October 30, 2007
Barrier Therapeutics, Inc. (NASDAQ: BTRX), apharmaceutical company developing and commercializing products in the fieldof dermatology, will release third quarter 2007 financial results onTuesday, October 30, 2007 at approximately 4:00 p.m. ET. The company willhost a conference call that day at 4:30 p.m. ET to provide a company updateand discuss...
Barrier Therapeutics Announces Promising Results From On-Going Phase 2a Study of Pramiconazole in Onychomycosis
Barrier Therapeutics, Inc. (NASDAQ: BTRX), apharmaceutical company that develops and markets dermatology products,today announced promising results from its on-going Phase 2aproof-of-concept study with pramiconazole, its novel oral broad-spectrumantifungal product candidate, in patients with onychomycosis nail fungusof the toenails. Pramiconazole has previously demonstrated positiveresults in clinical studies in tinea pedis...
Barrier Therapeutics to Present at the Natixis Bleichroeder Hidden Gems Conference
Barrier Therapeutics, Inc. (NASDAQ: BTRX), apharmaceutical company that develops and markets dermatology products,today announced that Mr. Al Altomari, Chief Operating Officer, and Ms. AnneVanLent, Executive Vice President and Chief Financial Officer, willparticipate in the Natixis Bleichroeder Hidden Gems Conference to be heldat the Carlton Hotel in New York on October...
Barrier Therapeutics Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Hyphanox(TM) for Onychomycosis
Barrier Therapeutics, Inc. (NASDAQ: BTRX), apharmaceutical company that develops and markets dermatology products,today announced that it has completed patient enrollment for its pivotalPhase 3 clinical study of HyphanoxTM, a novel patented oral formulationof the antifungal agent itraconazole, for the treatment of toenailonychomycosis nail fungus. "The completion of enrollment in this...
Barrier Therapeutics Completes $31.9 Million Registered Direct Offering of Common Stock
Barrier Therapeutics, Inc. (NASDAQ: BTRX), apharmaceutical company developing and commercializing products in the fieldof dermatology, today announced that it has completed the sale ofapproximately 5.5 million shares of its common stock through a registereddirect offering for $5.75 per share with select institutional investors,resulting in gross proceeds of approximately $31.9 million....
Barrier Therapeutics to Raise $31.9 Million in Registered Direct Offering of Common Stock
Barrier Therapeutics, Inc. (NASDAQ: BTRX), apharmaceutical company developing and commercializing products in the fieldof dermatology, today announced that it has priced a registered directoffering of its common stock for approximately $31.9 million in grossproceeds. Under the terms of the financing, Barrier will sellapproximately 5.5 million shares of its common...
Barrier Therapeutics to Present at Investor Conferences During September 2007
Barrier Therapeutics, Inc. (NASDAQ: BTRX), apharmaceutical company developing and commercializing products in the fieldof dermatology, today announced that Dr. Geert Cauwenbergh, Chief ExecutiveOfficer, and Mr. Al Altomari, Chief Operating Officer, will present anoverview of the Company's business activities and product pipeline atselect investor conferences during the month of September. The...
- Next »
- page 1 of 10
- « Previous
- Incorporated: 2001
- CEO: Mr. Alfred Altomari
- Employees: 130
Barrier Therapeutics is a pharmaceutical company focused on the development and commercialization of pharmaceutical products in the field of dermatology. As of Dec 31 2007, Co. marketed three pharmaceutical products, namely Vusion®, Xolegel® and Solagé® in the U.S. Co. also has product candidates in various stages of clinical development including Hyphanox™, Pramiconazole, Oral Rambazole™, Topical Rambazole and Hivenyl for the treatment of a range of dermatological conditions, including onychomycosis, psoriasis, acne, skin allergies and superficial fungal infections. Co. markets its products to dermatologists and other target physicians via its sales force and co-promotion agreement.
Key Competitors
Barrier Therapeutics Inc. Company Info
Board of Directors
Mr. Peter Ernster
Chairman
Mr. Alfred Altomari
Dr. Geert Cauwenbergh Ph.D.
Dr. Srinivas Akkaraju Ph.D.
Mr. Robert E. Campbell
Mr. Edward L. Erickson
Dr. Carl W. Ehmann M.D.
Mr. Charles F. Jacey Jr.
Ms. Carol Raphael
Contact Information
600 College Road East,
Suite 3200
Princeton, NJ
http://www.barriertherapeutics.com
609 945-1200
